- Home
- AKBA vs NEN Comparison
AKBA vs NEN Comparison
Compare AKBA & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- NEN
- Stock Information
- Founded
- AKBA 2007
- NEN 1977
- Country
- AKBA United States
- NEN United States
- Employees
- AKBA N/A
- NEN N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- NEN Building operators
- Sector
- AKBA Health Care
- NEN Real Estate
- Exchange
- AKBA Nasdaq
- NEN Nasdaq
- Market Cap
- AKBA 336.2M
- NEN 282.1M
- IPO Year
- AKBA 2014
- NEN N/A
- Fundamental
- Price
- AKBA $2.37
- NEN $82.70
- Analyst Decision
- AKBA Strong Buy
- NEN
- Analyst Count
- AKBA 1
- NEN 0
- Target Price
- AKBA $7.50
- NEN N/A
- AVG Volume (30 Days)
- AKBA 2.4M
- NEN 7.4K
- Earning Date
- AKBA 03-13-2025
- NEN 01-01-0001
- Dividend Yield
- AKBA N/A
- NEN 1.98%
- EPS Growth
- AKBA N/A
- NEN 67.91
- EPS
- AKBA N/A
- NEN 3.91
- Revenue
- AKBA $169,879,000.00
- NEN $81,169,352.00
- Revenue This Year
- AKBA N/A
- NEN N/A
- Revenue Next Year
- AKBA $30.85
- NEN N/A
- P/E Ratio
- AKBA N/A
- NEN $20.71
- Revenue Growth
- AKBA N/A
- NEN 10.81
- 52 Week Low
- AKBA $0.80
- NEN $67.19
- 52 Week High
- AKBA $2.48
- NEN $84.00
- Technical
- Relative Strength Index (RSI)
- AKBA 75.15
- NEN 53.23
- Support Level
- AKBA $1.72
- NEN $80.88
- Resistance Level
- AKBA $2.00
- NEN $82.74
- Average True Range (ATR)
- AKBA 0.11
- NEN 0.02
- MACD
- AKBA 0.04
- NEN 0.03
- Stochastic Oscillator
- AKBA 100.00
- NEN 85.28
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.